As of 2025-05-21, the Intrinsic Value of Korea Arlico Pharm Co Ltd (260660.KQ) is 8,130.14 KRW. This 260660.KQ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 7,460.00 KRW, the upside of Korea Arlico Pharm Co Ltd is 9.00%.
The range of the Intrinsic Value is 4,974.54 - 16,419.56 KRW
Based on its market price of 7,460.00 KRW and our intrinsic valuation, Korea Arlico Pharm Co Ltd (260660.KQ) is undervalued by 9.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 4,974.54 - 16,419.56 | 8,130.14 | 9.0% |
| DCF (Growth 10y) | 14,715.52 - 41,212.11 | 22,045.66 | 195.5% |
| DCF (EBITDA 5y) | 9,968.04 - 25,457.80 | 14,348.32 | 92.3% |
| DCF (EBITDA 10y) | 16,616.42 - 39,623.37 | 23,221.87 | 211.3% |
| Fair Value | -1,747.57 - -1,747.57 | -1,747.57 | -123.43% |
| P/E | (3,124.66) - (4,410.87) | (3,538.83) | -147.4% |
| EV/EBITDA | (1,126.01) - 7,489.29 | 3,125.08 | -58.1% |
| EPV | (6,680.11) - (7,959.81) | (7,319.96) | -198.1% |
| DDM - Stable | (3,611.70) - (11,727.25) | (7,669.47) | -202.8% |
| DDM - Multi | 8,146.13 - 20,858.71 | 11,753.95 | 57.6% |
| Market Cap (mil) | 114,361.80 |
| Beta | 0.37 |
| Outstanding shares (mil) | 15.33 |
| Enterprise Value (mil) | 149,334.70 |
| Market risk premium | 5.82% |
| Cost of Equity | 7.73% |
| Cost of Debt | 6.43% |
| WACC | 7.28% |